Director Lang James Paul buys 321,408 shares of OPRX at $7.60; holdings surge 472.4% to 389,452 shares.
Director Lang James Paul purchased 321,408 shares at $7.60 on 2025-03-14, increasing his stake from 68,044 to 389,452 shares—a 472.4% expansion of his prior holdings worth $2,443,761.45. This substantial open-market accumulation occurred near the low end of the 52-week range ($3.82–$13.17), at a 34.6% discount from the 52-week high. OptimizeRx is currently unprofitable with a negative $-9,124,000.00 net income on quarterly revenue of $21,309,000.00, though the company has achieved 14.5% annual revenue growth. The magnitude and concentration of this purchase—in a single transaction—is material and warrants analysis of the director's business outlook and capital allocation priorities given the company's present loss position.